NMRD vs. DYNT, QNRX, RSLS, INVO, TNON, OSAP, OSA, GMVDF, IONM, and BJDX
Should you be buying Nemaura Medical stock or one of its competitors? The main competitors of Nemaura Medical include Dynatronics (DYNT), Quoin Pharmaceuticals (QNRX), ReShape Lifesciences (RSLS), INVO Bioscience (INVO), Tenon Medical (TNON), ProSomnus (OSAP), ProSomnus (OSA), G Medical Innovations (GMVDF), Assure (IONM), and Bluejay Diagnostics (BJDX). These companies are all part of the "surgical & medical instruments" industry.
Nemaura Medical (NASDAQ:NMRD) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Dynatronics has higher revenue and earnings than Nemaura Medical. Dynatronics is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Dynatronics had 1 more articles in the media than Nemaura Medical. MarketBeat recorded 1 mentions for Dynatronics and 0 mentions for Nemaura Medical. Nemaura Medical's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.
4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 41.6% of Nemaura Medical shares are owned by company insiders. Comparatively, 9.1% of Dynatronics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Nemaura Medical currently has a consensus price target of $2.50, suggesting a potential upside of 8,096.72%. Dynatronics has a consensus price target of $3.80, suggesting a potential upside of 735.16%. Given Nemaura Medical's stronger consensus rating and higher probable upside, equities analysts clearly believe Nemaura Medical is more favorable than Dynatronics.
Dynatronics received 305 more outperform votes than Nemaura Medical when rated by MarketBeat users. However, 57.14% of users gave Nemaura Medical an outperform vote while only 50.91% of users gave Dynatronics an outperform vote.
Nemaura Medical has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Dynatronics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
Nemaura Medical has a net margin of 0.00% compared to Dynatronics' net margin of -14.13%. Nemaura Medical's return on equity of 0.00% beat Dynatronics' return on equity.
Summary
Nemaura Medical beats Dynatronics on 11 of the 17 factors compared between the two stocks.
Get Nemaura Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nemaura Medical Competitors List
Related Companies and Tools
